About us|Cardiac Arrest|LUCAS CPR|For users|News & Media|Contact|

News archive

Major breakthrough for Jolife at American Heart Association Congress

29th of November 2007, Lund, Sweden

Jolife, which develops and markets LUCAS, a mechanical chest compression system for patients suffering from cardiac arrest, made its biggest breakthrough yet at the world’s largest cardiologist meeting, the American Heart Association Congress. No fewer than four separate studies were presented at the congress, all with positive data. LUCAS is a safe and effective aid in resuscitating patients following cardiac arrest.

Jolife is in an expansive phase. LUCAS, its mechanical chest compression system for patients suffering from cardiac arrest, has been on the market since 2003. LUCAS is used primarily in emergency care to resuscitate patients with the help of mechanical chest compressions, and can, for example, be found in all ambulances in the Skåne region in southern Sweden. The launch of LUCAS in the USA, the world’s largest market, began in the spring. The studies presented at the American Heart Association’s congress earlier this month have enhanced LUCAS’s potential in the US market.

“We already knew that LUCAS is an effective aid in resuscitating patients following cardiac arrest,” says Erik von Schenck, CEO of Jolife. “This has now been confirmed to the rest of the world through the four studies with convincing data that were presented at the American Heart Association Congress. These studies provide solid and important documentation which further strengthens the product.”

Of the four studies presented at the American Heart Association Congress, two were conducted by professor Sten Rubertsson’s research group at Uppsala University Hospital in Sweden. The first, a randomised pilot study, compared manual and mechanical compressions and suggested a trend, although not a significant one, towards increased early survival of cardiac arrest patients receiving compressions with LUCAS. The second, which also compared LUCAS with manual compressions, showed that the use of LUCAS is safe in terms of injuries.

The first US studies of LUCAS to be presented included a comparison with an older US machine for chest compressions, which showed that LUCAS results in better blood flow and fewer rib fractures. The other US study showed that it is possible to defibrillate during LUCAS compressions with good effect. More information on these studies can be found at www.lucas-cpr.com.

“LUCAS has a wealth of benefits which have now been confirmed by these studies,” says Erik von Schenck. “We hope that this will raise awareness of the need for effective chest compressions to resuscitate patients following cardiac arrest, and fuel interest in LUCAS as a natural part of modern emergency care.”

The LUCAS™ chest compression system helps ambulance and hospital personnel to save patients suffering from sudden cardiac arrest by performing continuous chest compressions to maintain the blood flow to the brain and heart. International resuscitation guidelines issued in 2005 stress the importance of effective and uninterrupted chest compressions before defibrillation. LUCAS performs chest compressions in accordance with these guidelines without risking variations in quality or tiring out personnel. The device also allows safe transportation and permits simultaneous defibrillation and angiography.

About Jolife AB
Jolife is dedicated to increasing the survival of people suffering from sudden cardiac arrest, and the number who survive with their quality of life intact. This is being achieved by leading research and development in the field in order to offer innovative products which define the future for the treatment of sudden cardiac arrest. The company was founded in 2000 and has since worked closely with leading physicians and paramedics on research and development. This work has led to groundbreaking knowledge about the physiological effects of cardiac arrest and the importance of high-quality chest compressions. The LUCAS chest compression system is available for sale in the USA, Europe and various other parts of the world. Based in Lund in southern Sweden, Jolife markets its products through an exclusive global distribution agreement with Physio-Control, Inc. - a division within Medtronic, except in Sweden, Norway and Finland where it sells direct. For further information, please visit www.jolife.com or www.lucas-cpr.com.

Jolife AB
Scheelevägen 17
223 70 Lund
Tel: +46 46 286 50 00 www.jolife.com

Latest news
Train on LUCAS™

Physio-Control Inc. / Jolife AB, Ideon Science Park, SE-223 70 Lund, Sweden, Tel: +46 (0) 46 286 50 00, Fax: +46 (0) 46 286 50 10, info@lucas-cpr.com
Powered by Publiciteta&Co